Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center)
Publication type: Journal Article
Publication date: 2024-12-04
SJR: —
CiteScore: —
Impact factor: —
ISSN: 27826430, 30335639
Abstract
Patients with relapsed or refractory (r/r) DLBCL, primary mediastinal B-cell lymphoma and early relapse (up to 2 years) FL have a poor prognosis and short overall survival. Standard second-line chemotherapy for patients under 60-65 years old with r/r DLBCL includes intensive chemotherapy courses with platinum drugs and autologous stem cell transplantation (ASCT). It is known that response to therapy is achieved only in half of patients against the background of standard chemotherapy. Addition of new targeted drugs can improve treatment outcomes. This paper presents the first results of adding Venetoclax to chemotherapy in patients with r/r aggressive B-cell lymphomas.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
0
Total citations:
0
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Butaev L. et al. Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center) // A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2024. pp. 25-33.
GOST all authors (up to 50)
Copy
Butaev L., Oleynik Y. A., Bulusov M., Subora A., Zherebtsova V. A., Sukhareva A., Urnova E. S., Kisilichina D., Ptushkin V. V., Astrelina T. A., Samoilov A. S. Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center) // A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2024. pp. 25-33.
Cite this
RIS
Copy
TY - JOUR
DO - 10.33266/2782-6430-2024-4-25-33
UR - https://klinvest.fmbafmbc.ru/archive/2024-4/25-33/
TI - Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center)
T2 - A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin
AU - Butaev, L.S.
AU - Oleynik, Yu. A.
AU - Bulusov, M.P.
AU - Subora, A.Yu.
AU - Zherebtsova, V A
AU - Sukhareva, A.M.
AU - Urnova, E. S.
AU - Kisilichina, D.G.
AU - Ptushkin, V V
AU - Astrelina, T A
AU - Samoilov, A S
PY - 2024
DA - 2024/12/04
PB - Burnasyan Federal Medical Biophysical Center Of Federal Medical Biological Agency
SP - 25-33
SN - 2782-6430
SN - 3033-5639
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2024_Butaev,
author = {L.S. Butaev and Yu. A. Oleynik and M.P. Bulusov and A.Yu. Subora and V A Zherebtsova and A.M. Sukhareva and E. S. Urnova and D.G. Kisilichina and V V Ptushkin and T A Astrelina and A S Samoilov},
title = {Use of Venetoclax in the Therapy of Patients with Relapsed or Refractory B-Cell (Experience of the s.p. Botkin Moscow Multidisciplinary Scientific and Clinical Center)},
journal = {A I Burnasyan Federal Medical Biophysical Center Clinical Bulletin},
year = {2024},
publisher = {Burnasyan Federal Medical Biophysical Center Of Federal Medical Biological Agency},
month = {dec},
url = {https://klinvest.fmbafmbc.ru/archive/2024-4/25-33/},
pages = {25--33},
doi = {10.33266/2782-6430-2024-4-25-33}
}